Drug
Genetic Aav5 Hrkp Rpgr
Genetic Aav5 Hrkp Rpgr: highest development phase Phase 3, developed by MeiraGTx. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- MeiraGTx
Trials
| Drug | Phase | Indication |
|---|---|---|
| Genetic: AAV5-hRKp.RPGR NCT04671433 | Phase 3 | X-Linked Retinitis Pigmentosa |
Latest
No recent events.
Follow Genetic Aav5 Hrkp Rpgr on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.